There is a long history of discovery and development in the field of functional urology. While current commercial research has slowed- there is still an unmet need for the development of new and selective pharmaceutical treatments for a wide range of urological conditions. These functional disorders can significantly impact quality of life and have a major economic impact.
In this session will highlight topics that include the incorporation of patient-based factors in drug design, how sensory modulation is crucial for the selective treatment of overactive bladder, a look to potential therapeutic strategies for management of LUTS and innovative approaches in diagnostics such as artificial intelligence which may help to predict and enhance patient outcomes.
| Time |
Speaker |
Topic |
| 09:00 |
Lori Birder |
Introduction |
| 09:10 |
John Heesakkers |
Goals for Pharmaceutical Discovery and Development- Patient based factors |
| 09:20 |
Chris Chapple |
The sensory system as a target for pharmaceutical therapy of overactive bladder |
| 09:30 |
Lori Birder |
Drug development in complex disorders: Rationale for using 8-aminopurines in the management of LUTS |
| 09:40 |
Howard Goldman |
Using Artificial Intelligence as a predictor for OAB treatment outcomes |
| 09:50 |
All |
Discussion, Questions & Answers |